Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label imatinib in refractory desmoplastic small round cell tumor (DSRCT) expressing PDGF-R and/or c-KIT
2005-001614-41Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in desmoplastic small round cell tumor (DSRCT), sponsored by Novartis. Started Feb 2007; status: completed.
02
Drugs
03
Conditions
desmoplastic small round cell tumor (DSRCT)
Beyond the preview
Go deeper on 2005-001614-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001614-41.